Table 2.
Odds of requiring transition to prednisone therapy after budesonide MMX initiation, among patients with UC, unadjusted and adjusted analyses
| Unadjusted OR (95% CI) | Adjusted OR a(95% CI) | |
|---|---|---|
| Gender, male | 2.64 (1.06–6.63) | 2.96 (1.12–7.77) |
| Age at diagnosis, years | ||
| ≤29 | 2.47 (1.05–5.82) | 3.10 (1.21–7.95) |
| >29 | Reference | Reference |
| Disease extent | ||
| Proctitis | 0.75 (0.15–3.75) | 0.55 (0.10–3.03) |
| Left-sided colitis | Reference | Reference |
| Extensive/pancolitis | 0.73 (0.32–1.69) | 0.60 (0.24–1.49) |
| Concomitant therapy at budesonide MMX initiation | ||
| No therapy | 0.85 (0.24–3.08) | 0.61 (0.15–2.49) |
| Aminosalicylate | Reference | Reference |
| Biologic and/or immunomodulator | 1.07 (0.45–2.54) | 0.88 (0.35–2.25) |
MMX, multimatrix; UC, ulcerative colitis.
a
All variables listed above were included in the final multivariable analysis.